01

Dr. Singh’s Review Favors DecisionDx in Melanoma GEP Testing

DecisionDx-Melanoma showed a >1% absolute mortality difference in a large SEER analysis, while MERLIN_001 missed its primary endpoint; NCCN defines low risk below 5% nodal involvement.